Circulating Exosomal Proteins as New Diagnostic Biomarkers for Colorectal Cancer (EXOSCOL01): A Pilot Case–Controlled Study Focusing on MMP14 Potential

IF 2.6 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Journal of Clinical Laboratory Analysis Pub Date : 2025-04-17 DOI:10.1002/jcla.70016

Mickaël Barhoum, Sylvie Brassart-Pasco, Aurélie Dupont-Deshorgue, Aurore Thierry, Lukshe Kanagaratnam, Bertrand Brassart, Fidy Ramaholimihaso, Damien Botsen, Claire Carlier, Mathias Brugel, Marine Perrier, Laurent Ramont, Olivier Bouché

{"title":"Circulating Exosomal Proteins as New Diagnostic Biomarkers for Colorectal Cancer (EXOSCOL01): A Pilot Case–Controlled Study Focusing on MMP14 Potential","authors":"Mickaël Barhoum, Sylvie Brassart-Pasco, Aurélie Dupont-Deshorgue, Aurore Thierry, Lukshe Kanagaratnam, Bertrand Brassart, Fidy Ramaholimihaso, Damien Botsen, Claire Carlier, Mathias Brugel, Marine Perrier, Laurent Ramont, Olivier Bouché","doi":"10.1002/jcla.70016","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. The French CRC screening campaign is based on fecal immunochemical tests (FIT), confirmed by colonoscopy, an invasive procedure with a poor participation rate. This study aimed to compare the expression of circulating exosomal proteins (MMP14, β1-Integrin subunit, β3-Integrin subunit, and α1(I) Collagen chain) in patients with CRC or adenomas.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 71 patients were recruited, including 24 controls (normal colonoscopy), 11 patients with adenoma, and 36 with CRC. Plasmatic exosomal protein expression was measured by western blot analysis and reported to either protein or exosome content.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The three groups were comparable regarding clinical characteristics. A significant difference was observed for MMP14 relative expression (<i>p</i> = 0.0007), MMP14 expression reported to exosomal protein content (<i>p</i> = 0.0003), and MMP14 expression reported to exosome content (<i>p</i> = 0.0005). These three parameters were significantly higher in patients with adenoma vs. control patients (<i>p</i> = 0.0013, <i>p</i> = 0.0004, and <i>p</i> = 0.0003, respectively). Only MMP14 relative intensity was significantly higher in the CRC group vs. the control group (<i>p</i> = 0.0018).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Exosomal MMP14 is a promising early diagnostic biomarker for CRC and adenoma. These preliminary results warrant confirmation in larger studies using quantitative measurements such as ELISA or flow cytometry.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"39 9","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.70016","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.70016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. The French CRC screening campaign is based on fecal immunochemical tests (FIT), confirmed by colonoscopy, an invasive procedure with a poor participation rate. This study aimed to compare the expression of circulating exosomal proteins (MMP14, β1-Integrin subunit, β3-Integrin subunit, and α1(I) Collagen chain) in patients with CRC or adenomas.

Methods

A total of 71 patients were recruited, including 24 controls (normal colonoscopy), 11 patients with adenoma, and 36 with CRC. Plasmatic exosomal protein expression was measured by western blot analysis and reported to either protein or exosome content.

Results

The three groups were comparable regarding clinical characteristics. A significant difference was observed for MMP14 relative expression (p = 0.0007), MMP14 expression reported to exosomal protein content (p = 0.0003), and MMP14 expression reported to exosome content (p = 0.0005). These three parameters were significantly higher in patients with adenoma vs. control patients (p = 0.0013, p = 0.0004, and p = 0.0003, respectively). Only MMP14 relative intensity was significantly higher in the CRC group vs. the control group (p = 0.0018).

Conclusions

Exosomal MMP14 is a promising early diagnostic biomarker for CRC and adenoma. These preliminary results warrant confirmation in larger studies using quantitative measurements such as ELISA or flow cytometry.

Abstract Image

查看原文本刊更多论文

循环外泌体蛋白作为结直肠癌新的诊断生物标志物（EXOSCOL01）：一项关注MMP14潜力的试点病例对照研究

结直肠癌（CRC）是全球癌症相关死亡的第二大原因。法国CRC筛查运动基于粪便免疫化学试验（FIT），结肠镜检查证实，这是一种参与率较低的侵入性手术。本研究旨在比较循环外泌体蛋白（MMP14、β1-整合素亚基、β3-整合素亚基和α1(I)胶原链）在结直肠癌或腺瘤患者中的表达。方法共招募71例患者，其中对照组24例（正常结肠镜检查），腺瘤患者11例，结直肠癌患者36例。通过western blot分析测定血浆外泌体蛋白表达，并报告蛋白或外泌体含量。结果三组患者的临床特征具有可比性。MMP14的相对表达量（p = 0.0007）、外泌体蛋白含量报告的MMP14表达量（p = 0.0003）和外泌体含量报告的MMP14表达量（p = 0.0005）存在显著差异。这三个参数在腺瘤患者中明显高于对照组（p = 0.0013, p = 0.0004, p = 0.0003）。只有CRC组的MMP14相对强度显著高于对照组（p = 0.0018）。结论外泌体MMP14是结直肠癌和腺瘤的早期诊断标志物。这些初步结果值得在更大规模的定量研究中得到证实，如ELISA或流式细胞术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Laboratory Analysis 医学-医学实验技术

CiteScore

5.60

自引率

7.40%

发文量

584

审稿时长

6-12 weeks

期刊介绍： Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.